Veterinary Portable Blood Test Machine Auto Blood Hemogram Hematology Analyzer with 8.4"LCD Display

Name: Veterinary Portable Blood Test Machine Auto Blood Hemogram Hematology Analyzer with 8.4"LCD Display
Brand: Karestar Technology (Xuzhou) Co., Ltd.
SKU: 2282782815

Jiangsu, ChinaKarestar Technology (Xuzhou) Co., Ltd.

US$299.00-2,099.00

1 units

Product profile

Customization

Available

Display

8.4 Inches Color Touch Screen

Methodology

Electrical Resistance for Counting and Sft Method

Model NO.

K-HA05

Parameter

3-Part Differentiation of Wbc;20 Parameters and 3

3-Part Differentiation of Wbc;20 Paramet

Venous 9.6UL,Pre-Diluted 20UL,Capillary 9.6UL

Venous 9.6UL,Pre-Diluted 20UL,Capillary

Venous 9.6UL,Pre-Diluted 20UL,Capillary 9.6UL

Throughput

More Than 40 Samples Per Hour,24 Hours Work with a

Storage

up to 50,000 Sample Results+3 Histograms

Operation Language

English,French, Spanish,Portuguese,Russian,etc

QC Control

X-B, L-J, X, SD, CV %

Calibration Mode

Manual Calibration and Automatic Calibration

Input /Output

4xusb, 1×RS232,1xethernet,1xvga(for External Monit

Temperature

15℃℃-35℃C, Humidity ≤10-90%

Air Pressure

70kpa-106kpa

Printer

Thermal Recorder, 57 mm Width Paper, Various Print

Power Supply

AC100~240V 50/60Hz

Transport Package

Carton Boxes

Trademark

Karestar

Origin

Jiangsu, China

Production Capacity

20000 Unit/Units Per Year

Company profile

Karestar Technology (Xuzhou) Co., Ltd.

Jiangsu, China

Business Type: Manufacturer/FactoryAverage Response Time: ≤2.41h

AI-Powered supplier vetting

SummaryKarestar Technology (Xuzhou) Co., Ltd. is identified as a China-based manufacturer/factory operating in medical and electronic equipment, including electrocardiographs, ultrasound scanners, patient monitors, and related products. It reports ISO 9000, ISO 13485, and ISO 9001 management-system certifications, automated production and testing equipment, and 6–10 quality-control staff, but only one production line is stated. The company reports exports to more than 60 countries and 90% of sales from exports, although the provided trade records show only one transaction in each of three product categories with one buyer in Uganda. Evidence supports product-development activity, including a patented electrocardiograph and a patient monitor, while R&D staffing, customization capability, financial strength, and after-sales performance are not sufficiently documented. No financial data or monetary figures are included.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is organized as a limited company in Jiangsu, China. This directly supports its status as a manufacturing supplier rather than only a trading intermediary.

CertificationsThe supplier states that it follows ISO 13485 and ISO 9001 production systems and lists ISO 9000, ISO 13485, and ISO 9001 under supplier management-system certifications. These stated certifications are relevant to medical-device quality management, although the slices do not provide certificate numbers, validity dates, or issuing bodies.

R&D capabilityThe supplier reports a professional R&D team, development of a patented electrocardiograph in 2019, and development and launch of a patient monitor in 2020. These are explicit indicators of product-development activity, although total R&D-engineer experience is listed as unavailable.

Production capacityThe supplier reports automated production and testing equipment, a quality-control team of 6–10 staff, and compliance with stated production systems. Capacity evidence is limited because only one production line is reported and annual output is described only broadly, so the information supports manufacturing capability but not high-volume capacity.

Client casesThe company claims exports to more than 60 countries and reports distributor authorization activity in Southeast Asia, the Middle East, and parts of Europe and the United States. Specific trade records identify YOGI LTD in Uganda for three product categories, each showing one transaction; these provide some customer and market evidence but limited independently detailed case history.